ROSG.Q Stock Overview
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rosetta Genomics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 0% |
| 3 Year Change | -99.88% |
| 5 Year Change | -98.82% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| ROSG.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -5.0% | -3.5% |
| 1Y | 0% | -1.7% | 20.2% |
Return vs Industry: ROSG.Q exceeded the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: ROSG.Q underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| ROSG.Q volatility | |
|---|---|
| ROSG.Q Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ROSG.Q has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ROSG.Q's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | n/a | www.rosettagenomics.com |
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company’s microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer.
Rosetta Genomics Ltd. Fundamentals Summary
| ROSG.Q fundamental statistics | |
|---|---|
| Market cap | US$592.00 |
| Earnings (TTM) | -US$9.48m |
| Revenue (TTM) | US$2.86m |
0.0x
P/S Ratio0.0x
P/E RatioIs ROSG.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROSG.Q income statement (TTM) | |
|---|---|
| Revenue | US$2.86m |
| Cost of Revenue | US$1.90m |
| Gross Profit | US$962.00k |
| Other Expenses | US$10.45m |
| Earnings | -US$9.48m |
Last Reported Earnings
Jun 30, 2017
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ROSG.Q perform over the long term?
See historical performance and comparison